Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YU1206
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
**YU1206** is a novel small molecule degrader targeting LRF (Leukemia/Lymphoma-Related Factor, also known as ZBTB7A), a transcriptional repressor that inhibits fetal hemoglobin (HbF) expression in adult erythroid cells. By inducing LRF degradation, YU1206 promotes HbF upregulation, mimicking the mechanism of approved HbF inducers like hydroxyurea or BCL11A-targeting therapies used in sickle cell disease and beta-thalassemia. Preclinical data demonstrate effective HbF induction without significantly impairing erythroid maturation or peripheral blood counts, positioning it as a potential oral therapeutic for hemoglobinopathies.[7]
Beyond the preview
Go deeper on YU1206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YU1206.